According to CoinMeta, Sinopharm Modern announced that its holding subsidiary, Sinopharm Yixin Pharmaceutical Co., Ltd., received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration, agreeing to withdraw the registration application for cyclophosphamide injection. Sinopharm Yixin submitted the marketing registration application for this product to the National Medical Products Administration in September 2023 and it was accepted. Due to the need for further improvement of research work, the National Medical Products Administration has recently agreed to withdraw the registration application and terminate the registration process. To date, Sinopharm Yixin has invested approximately 12.747 million yuan (unaudited) in the research and development of cyclophosphamide injection. This withdrawal will not have a significant impact on the company's current operating performance.